Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 454 participants.

Also called NCT01692301

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 454 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01692301
  • EudraCT 2012-002899-14
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Colombia, France, Germany, Greece, Italy, Japan, Russia, South Korea, Spain, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01692301. Randomized; double masking; primary purpose treatment. Start 2012-12 (registry gives no type); primary completion 2015-04 (actual). Results posted on 2016-05-04.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension
Condition
Hypertension
Intervention (Drug)
LCZ696
Intervention (Drug)
Olmesartan
Intervention (Drug)
LCZ696 matching placebo
Intervention (Drug)
Olmesartan matching placebo
Intervention (Drug)
amlodipine
Intervention (Drug)
hydrochlorothiazide
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01692301
Content hash
22165650e9c7536d675c02dec5e8b17c2b0a40ee83f4b6591362fb5aad929acd